Trastuzumab treatment was associated significantly with an increase in tumor-associated NK cells and lymphocytes expressing granzyme B and TiA1, supporting a role for the immune response in the antibody mechanisms of action in patients with breast cancer receiving NAC [37]. The gene discussed is GZMB; the disease is breast carcinoma.